https://www.ncbi.nlm.nih.gov/pubmed/30585764
Cancer Biotherapy & Radiopharmaceuticals; Song B, Wang L et. al.
Dec 26th, 2018 - Breast cancer (BC) is a common malignant tumor in females. The combined assay of multiple molecular markers benefits the diagnosis and prognostic prediction. Human epidermal growth factor receptor 2 (HER2) facilitates the proliferation and differentiation of cancer cells through ligand binding. Ki67 is a tumor proliferation-related gene, whereas GSTP1 i...
https://www.ncbi.nlm.nih.gov/pubmed/24324107
Anticancer Research; Miyake T, Nakayama T et. al.
Dec 11th, 2013 - We investigated the association of glutathione S-transferase P1 (GSTP1) expression and methylation status with clinicopathological characteristics of estrogen receptor (ER)-positive breast cancers. Primary ER-positive breast cancerpatients (n=177, stage I-III) were retrospectively analyzed. A quantitative GSTP1methylation assay was performed using DNA...
https://www.ncbi.nlm.nih.gov/pubmed/23135572
Breast Cancer Research and Treatment; Milde-Langosch K, Karn T et. al.
Nov 9th, 2012 - High proliferation rates are characteristic of cancer, and proliferation markers make up the majority of genes included in RNA-based prognostic gene signatures applied for breast cancer patients. Based on prior data on differences in molecular subgroups of breast cancer, we hypothesized that the significance of single proliferation markers might differ ...
https://www.ncbi.nlm.nih.gov/pubmed/29436103
Genes, Chromosomes & Cancer; Fimereli D, Fumagalli D et. al.
Feb 13th, 2018 - The advent of next generation sequencing technologies has boosted the interest in exploring the role of fusion genes in the development and progression of solid tumors. In breast cancer, most of the detected gene fusions seem to be "passenger" events while the presence of recurrent and driver fusions is still under study. We performed RNA sequencing in 55 well-characterized...
https://www.ncbi.nlm.nih.gov/pubmed/25648141
BMC Medical Genetics; Savukaitytė A, Ugenskienė R et. al.
Feb 5th, 2015 - Breast cancer is the most frequent oncological disease among women. Estrogens are known to play an important role in breast cancer development. Recognition of the relationship between polymorphisms within estrogen metabolizing genes and conventional prognostic factors of breast cancer might improve our knowledge on individualized breast
https://www.ncbi.nlm.nih.gov/pubmed/30170623
Diagnostic Pathology; Völker HU, Weigel M et. al.
Aug 31st, 2018 - Conventional parameters including Ki67, hormone receptor and Her2/neu status are used for risk stratification for breast cancer. The serine protease urokinase plasminogen activator (uPA) and the plasminogen activator inhibitor type-1 (PAI-1) play an important role in tumour invasion and metastasis. Increased concentrations in tumour tissue are associated with more ag...
https://www.ncbi.nlm.nih.gov/pubmed/18485221
Breast Cancer Research : BCR; Sunami E, Shinozaki M et. al.
May 20th, 2008 - Estrogen receptor (ER)-positive breast cancers are considered prognostically more favorable than ER-negative tumors, whereas human epidermal growth factor receptor (HER)2/neu-positive breast cancers are associated with worse prognosis. The objective of the present study was to determine whether ER-positive and ER-negative status relates to epigenetic changes in br...
https://www.ncbi.nlm.nih.gov/pubmed/20696638
European Journal of Medical Research; Matuschek C, Bölke E et. al.
Aug 11th, 2010 - Tumor-related methylated DNA and circulating tumor cells (CTC) in the peripheral blood might be of prognostic importance in breast cancer. Thus, the aim of our study was to examine free methylated DNA and CTC in the blood from breast cancer patients and to correlate it with clinicopathological features known to influence prognosis. We prospectively obtained serum sam...
https://www.ncbi.nlm.nih.gov/pubmed/29540052
Cancer Research and Treatment : Official Journal of Korean Cancer Association; Deng L, Zhu X et. al.
Mar 15th, 2018 - The prevalence of PIK3CA in Chinese breast cancer patients may be underestimated. Therefore, we investigated the distribution of somatic PIK3CA/AKT1 mutations in Chinese breast cancer patients and explored their roles in tumor phenotypes and disease prognosis. Tumors from five hundred and seven breastcancer patients were prospectively collected from th...
https://www.ncbi.nlm.nih.gov/pubmed/24129975
Breast Cancer Research and Treatment; Murria Estal R, Palanca Suela S et. al.
Oct 17th, 2013 - This study aims to identify signatures of miR associated with hereditary, BRCA1 or BRCA2 mutation positive breast cancer (BC), and non-hereditary BC, either sporadic (SBC) or non-informative (BRCAX). Moreover, we search for signatures associated with tumor stage, immunohistochemistry and tumor molecular profile. Twenty formalin fixed paraffin embedded (FFPE) BCs, BRCA1, BRCA2, BRC...
https://www.ncbi.nlm.nih.gov/pubmed/25370037
European Journal of Human Genetics : EJHG; Yamamoto-Ibusuki M, Yamamoto Y et. al.
Nov 6th, 2014 - Genome-wide association studies have identified a single-nucleotide polymorphism (SNP) to be associated with an increased risk of breast cancer. The biology of one of the susceptibility locus C6ORF-ESR1 and whether it also contributes to progression of established disease has not yet been ascertained. We examined the association of rs2046210 and its six linkage disequilibrium SNPs...
https://www.ncbi.nlm.nih.gov/pubmed/29718092
Annals of Oncology : Official Journal of the European Society for Medical Oncology; Hortobagyi GN, Stemmer SM et. al.
Apr 27th, 2018 - The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Here we report updated efficacy and sa...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,